CervoMed Inc. Cash Flow Conversion Efficiency
CervoMed Inc. cash flow conversion efficiency. Based on the latest financial reports, CervoMed Inc. (CRVO) has a cash flow conversion efficiency ratio of -0.301x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.92 Million) by net assets ($22.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of CervoMed Inc. (1998–2025)
Cash flow conversion efficiency of CervoMed Inc. from 1998 to 2025. This chart illustrates how CervoMed Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View CRVO share price today for real-time trading data and today's change.
CervoMed Inc. Cash Flow Conversion Ratio Explained
CervoMed Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
CervoMed Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CervoMed Inc. ranked by their cash flow conversion efficiency. Also see CervoMed Inc. market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hennessy Capital Investment Corp. VII Ordinary Shares
NASDAQ:HVII
|
-0.001x |
|
Grand Kartech Tbk
JK:KRAH
|
0.061x |
|
EMB Mission Bound AB (publ)
ST:NAVIGO-STAM
|
0.033x |
|
Almaden Minerals Ltd
TO:AMM
|
-0.200x |
|
Veto Switchgears And Cables Limited
NSE:VETO
|
0.036x |
|
Aligos Therapeutics Inc
NASDAQ:ALGS
|
-0.728x |
|
FTC Solar Inc
NASDAQ:FTCI
|
-0.273x |
|
SFD SA ZY -10
F:7PQ
|
0.072x |
Annual Cash Flow Conversion Efficiency for CervoMed Inc. (1998–2025)
The table below shows the annual cash flow conversion efficiency of CervoMed Inc. from 1998 to 2025. Review CRVO FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.22 Million | $-23.45 Million | -1.287x | -205.17% |
| 2024-12-31 | $39.20 Million | $-16.53 Million | -0.422x | +58.25% |
| 2023-12-31 | $7.38 Million | $-7.45 Million | -1.010x | -453.20% |
| 2022-12-31 | $-9.00 Million | $-2.57 Million | 0.286x | +168.83% |
| 2021-12-31 | $34.91 Million | $-14.50 Million | -0.415x | +23.94% |
| 2020-12-31 | $24.81 Million | $-13.55 Million | -0.546x | -11.55% |
| 2019-12-31 | $20.13 Million | $-9.86 Million | -0.490x | +29.04% |
| 2018-12-31 | $15.61 Million | $-10.77 Million | -0.690x | -18.79% |
| 2017-12-31 | $21.23 Million | $-12.33 Million | -0.581x | +50.45% |
| 2016-12-31 | $9.18 Million | $-10.77 Million | -1.172x | -100.94% |
| 2015-12-31 | $-41.62K | $-5.19 Million | 124.578x | +52752.75% |
| 2014-12-31 | $38.17 Million | $-9.03 Million | -0.237x | -29.13% |
| 2013-12-31 | $6.47 Million | $-1.18 Million | -0.183x | -178.24% |
| 2012-12-31 | $-18.41 Million | $-4.31 Million | 0.234x | -68.84% |
| 2011-12-31 | $-16.00 Million | $-12.02 Million | 0.751x | +100.77% |
| 2010-12-31 | $20.22K | $-1.98 Million | -97.964x | -4474.39% |
| 2009-12-31 | $493.60K | $-1.06 Million | -2.142x | -85.81% |
| 2008-12-31 | $438.99K | $-505.95K | -1.153x | +61.74% |
| 1999-12-31 | $2.77 Million | $-8.35 Million | -3.012x | -133.32% |
| 1998-12-31 | $5.50 Million | $-7.10 Million | -1.291x | -- |
About CervoMed Inc.
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood"brain barrier and inhibits the enzyme p38a. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and sl… Read more